Table 2.

Baseline and follow-up mean (SD) values of bone mineral density (BMD) and laboratory parameters in the two treatment groups.

	Months	Denosumab (n=51)	Bisphosphonates (n=62)	p Value*
BMD lumbar spine	0	0.83(0.14)	0.84(0.10)	0.77
	12	0.89(0.14)	0.87(0.11)
	p Value**	0.0001	0.09
BMD femoral neck	0	0.69(0.07)	0.69(0.06)	0.98
	12	0.75(0.09)	0.71(0.07)
	P Value	0.0001	0.001
T score femoral neck	0	-2.34(0.59)	-2.47(0.56)	0.54
	12	-1.90(0.74)	-2.27(0.59)
	P Value	0.0001	0.0014
Calcium	0	9.59(0.48)	9.42(0.53)	0.18
	12	9.59(0.49)	9.45(0.45)
	P Value	0.91	0.84
Phosphate	0	3.45(0.5)	3.55(0.45)	0.16
	12	3.27(0.5)	3.45(0.45)
	P Value	0.02	0.13
Parathyroid Hormone (PTH)	0	44.87(17.54)	45.79(14.74)	0.82
	12	53.25(15.77)	49.64(20.67)
	P Value	0.04	0.25
25OH Vitamin D	0	28.82(11.66)	25.10(12.10)	0.12
	12	31.09(8.89)	26.11(12.41)
	P Value	0.14	1

^*: p value, t-test for unpaired observations, comparisons between baseline values of the two treatment groups.

^**: p value, t-test for paired observations, comparisons within treatment group.

Statistical significance was set at the level of p<0.05.